Pressure BioSciences Inc. PBIO Archives - Page 19 of 22

WednesdayJun 27, 2018 3:25 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Recent Equity Swap Boosts Plans to Uplist

Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) recently announced a debt-to-equity swap, resulting in a total loan debt amount that company management sees as manageable. An article further discussing the company reads: “Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step forward as yet another group of debt holders have agreed to a debt-to-equity swap, this time amounting to $7.24 million, representing a strong message of investor support. The total amount of debt that has been converted to equity is now over $13.6 million, all in…

MondayJun 18, 2018 11:10 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) President and CEO Discusses Recent Company Activities in Interview on Uptick Newswire’s “Stock Day” Podcast

Global life sciences company Pressure BioSciences Inc.’s (OTCQB: PBIO) president and CEO Richard T. Schumacher was recently interviewed on Uptick Newswire’s “Stock Day” podcast. Among other highlights of the interview, Schumacher discussed the company’s sustained financial success, the noteworthy amount of debt it has converted into equity over the past 30 days, and upcoming plans for the company. Such plans include the company’s goal to up-list to a national exchange by the end of the year. PBIO is working diligently to meet the necessary requirements to up-list. “Although we are a QB company on the OTC Marketplace, we run the…

WednesdayJun 13, 2018 11:03 am

Pressure BioSciences, Inc. (PBIO) Announces $7.24M Debt-to-Equity Swap as it Prepares for 2018 Uplisting to National Stock Exchange

Equity swap further boosts Pressure BioSciences’ plans to uplist to a major stock exchange later this year Latest deal brings total debt-to-equity conversions to over $13.6M in past 30 days 2015/2016 debentures, line-of-credit and promissory note, plus various short-term debt, now converted to equity Company’s recently acquired Pre-EMT™ platform, allowing for improved protein-based drug development, has significant market potential and adds to a string of technological developments Pressure BioSciences Inc.’s (OTCQB: PBIO) ambitions to achieve listing on a major stock exchange this year have taken another major step forward as yet another group of debt holders have agreed to a…

TuesdayJun 12, 2018 10:30 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Announces Conversion of Additional $7.24M of Debt into Equity

Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) this morning announced the conversion of an additional $7.24 million of debt into equity, bringing the total amount of debt that has converted into equity over the past four weeks to $13.6 million. “With today's announced conversion of an additional $7.24M of debt to equity, total loan debt has been reduced from approximately $16.6M to approximately $3.0M, which is a level we believe the Company can manage,” Joseph L. Damasio, VP of finance and CFO of PBIO, stated in the news release. “We are continuing to discuss the Company's progress with…

FridayJun 01, 2018 10:57 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Boosts Drug Development Process through Acquisition of PreEMT™ Platform

Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently acquired the PreEMT™ platform to develop a unique manufacturing method and improve the quality of a key protein-based drug being developed. A recent article discussing the company reads: “The acquisition of the PreEMT technology gives PBIO a footprint in the very large and growing biologics contract research services sector. The company is also busily developing its recently patented Ultra Shear Technology (UST) platform. The scalable, pressure-based UST technology creates stable nanoemulsions of otherwise immiscible fluids. It can be used to extend the shelf life of homogenized dairy products without refrigeration, for…

WednesdayMay 30, 2018 2:11 pm

Pressure BioSciences Inc.’s (PBIO) Recently Acquired PreEMT™ Platform Enhances Development of Biotherapeutic Protein Drugs

Biologics offer novel ways of treating degenerative diseases like Alzheimer’s Biologics are one of the fastest-growing drug categories PreEMT™ technology improves quality, reduces cost of biologic manufacture When we think of drugs, an image of potions in round-bottom flasks conjured up in labs comes to mind, or perhaps pills of one sort or another ingested with a sip of water, for about 90 percent of drugs currently in use have that profile. However, discovering that the human body will act as its own physician by dispensing protective proteins called antibodies to fight the toxins that bring on diseases has spurred…

FridayMay 25, 2018 11:11 am

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Increase in Revenue, Debt Conversion in Q1 2018

Global life sciences company Pressure BioSciences (OTCQB: PBIO) recently announced financial results for the first quarter ended March 31, 2018. Among other highlights, the company reported first quarter revenue growth and debenture conversion. An article discussing the report further reads: “The first quarter of 2018 was the ninth consecutive quarter in which the company reported an increase in products and services revenue on a year-over-year basis and the second time during the past year in which the company reported total quarterly revenue of more than $600,000. Sales of the company’s instruments established a new quarterly record, and sales of the…

FridayMay 18, 2018 2:07 pm

Revenue Growth, Debt Conversion Boost Pressure BioSciences’ (PBIO) Outlook at Close of First Quarter

High-pressure lab equipment maker reports ninth consecutive quarter of revenue growth (Y/Y) About 92 percent of debenture debt converted to preferred stock, with aim of uplisting to national stock exchange Patented technologies continue to drive optimism for company’s products to enhance and improve scientific research Pressure BioSciences, Inc. (OTCQB: PBIO), the maker of a patented and powerful line of pressure-based scientific laboratory tools, celebrated corporate gains on May 15 with the announcement of first quarter revenue growth and debenture conversion. The first quarter of 2018 was the ninth consecutive quarter in which the company reported an increase in products and…

TuesdayMay 15, 2018 2:03 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Reports Q1 Financial Results, Provides Business Update; Schedules Earnings Call

Global life sciences company Pressure BioSciences (OTCQB: PBIO) today announced financial results for the first quarter ended March 31, 2018. Among other highlights, Pressure BioSciences reported total revenue of $610,774 for the first quarter of 2018 compared to $551,357 for the same period in 2017, demonstrating an increase of 11%. The company attributes the increase in revenue primarily to its growth in products and services which brought in $585,244 for the first quarter of 2018 compared to $525,998 for the same quarter of 2017, similarly demonstrating an 11% increase. The company also provided a business update and offered limited guidance…

ThursdayMay 03, 2018 12:18 pm

QualityStocksNewsBreaks – Pressure BioSciences Inc. (PBIO) Enters Agreement Related to Recently Acquired PreEMT™ Platform

Global life sciences company Pressure BioSciences Inc. (OTCQB: PBIO) today announced that it has signed an agreement with an international biopharmaceutical company to assess the potential of PBIO’s recently acquired PreEMT™ platform to develop a unique manufacturing process and improve the quality of a key protein-based drug that’s currently under development. “We believe this contract will take three to four months to complete. Moreover, we have recently been contacted by several additional biopharmaceutical companies interested in evaluating our PreEMT disaggregation and refolding service in the development and manufacture of protein-based therapeutics,” Richard T. Schumacher, president and CEO of PBIO, stated…

Site Search

Company Search

Tag: Pressure BioSciences Inc. PBIO